cobimetinib
Ligand Summary
Cobimetinib is a reversible inhibitor of mitogen-activated protein kinase (MAPK)/extracellular signal regulated kinase 1 (MEK1) and MEK2. MEK proteins are upstream regulators of the extracellular signal-related kinase (ERK) pathway, which promotes cellular proliferation. BRAF V600E and K mutations result in constitutive activation of the BRAF pathway which includes MEK1 and MEK2. In mice implanted with tumor cell lines expressing BRAF V600E, cobimetinib inhibited tumor cell growth.
UNII: ER29L26N1X
PubChem: 16222096
Guide to Pharmacology: 7626
ChEMBL: CHEMBL2146883
DrugCentral: 5046
LyCHI: 8UDBJA4F9RNN
Target Activities
10 Activities
Items per page:
10
1 – 10 of 10
Activity Type | Activity Value -log(M) | Mechanism of Action | Activity Reference | Publications (PubMed IDs) | ||
---|---|---|---|---|---|---|
IC50 | ||||||
IC50 | ||||||
IC50 | ||||||
Kd | ||||||
IC50 | ||||||
IC50 | ||||||
IC50 | ||||||
Kd | ||||||
IC50 | INHIBITOR | |||||
Kd | ||||||